Literature DB >> 18046102

Masked hypertension definition, impact, outcomes: a critical review.

Dimitris P Papadopoulos1, Thomas K Makris.   

Abstract

The phenomenon of masked hypertension (MH) is defined as a clinical condition in which a patient's office blood pressure (BP) level is <140/90 mm Hg but ambulatory or home BP readings are in the hypertensive range. The prevalence in the population is about the same as that of isolated office hypertension; about 1 in 7 or 8 persons with a normal office BP level may fall into this category. The high prevalence of MH would suggest the necessity for measuring out-of-office BP in persons with apparently normal or well-controlled office BP. Reactivity to daily life stressors and behavioral factors such as smoking, alcohol use, contraceptive use in women, and sedentary habits can selectively influence MH. MH should be searched for in individuals who are at increased risk for cardiovascular complications including patients with kidney disease or diabetes. Individuals with MH have been shown to have a greater-than-normal prevalence of organ damage, particularly with an increased prevalence of metabolic risk factors, left ventricular mass index, carotid intima-media thickness, and impaired large artery distensibility compared with patients with a truly normal BP level in and out of the clinic or office. Also, outcome studies have suggested that MH increases cardiovascular risk, which appears to be close to that of in-office and out-of-office hypertension. The aim of this review was to define the entity of MH, to describe its prevalence in the general population, and to discuss its correlation with cardiovascular events.

Entities:  

Mesh:

Year:  2007        PMID: 18046102      PMCID: PMC8109935          DOI: 10.1111/j.1524-6175.2007.07418.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  59 in total

1.  Detection of carotid atherosclerosis in individuals with masked hypertension and white-coat hypertension by self-measured blood pressure at home: the Ohasama study.

Authors:  Azusa Hara; Takayoshi Ohkubo; Masahiro Kikuya; Yoriko Shintani; Taku Obara; Hirohito Metoki; Ryusuke Inoue; Kei Asayama; Takanao Hashimoto; Toshiya Harasawa; Yoko Aono; Harunori Otani; Kazushi Tanaka; Junichiro Hashimoto; Kazuhito Totsune; Haruhisa Hoshi; Hiroshi Satoh; Yutaka Imai
Journal:  J Hypertens       Date:  2007-02       Impact factor: 4.844

2.  Morning blood pressure predicts hypertensive organ damage in patients with renal diseases: effect of intensive antihypertensive therapy in patients with diabetic nephropathy.

Authors:  Satoru Kuriyama; Yasushi Otsuka; Rinako Iida; Kei Matsumoto; Goro Tokudome; Tatsuo Hosoya
Journal:  Intern Med       Date:  2005-12       Impact factor: 1.271

3.  Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure.

Authors:  R H Fagard; J A Staessen; L Thijs
Journal:  Hypertension       Date:  1997-01       Impact factor: 10.190

Review 4.  Resistant hypertension: diagnosis and management.

Authors:  Dimitris P Papadopoulos; Vasilios Papademetriou
Journal:  J Cardiovasc Pharmacol Ther       Date:  2006-06       Impact factor: 2.457

5.  Masked hypertension assessed by ambulatory blood pressure versus home blood pressure monitoring: is it the same phenomenon?

Authors:  George S Stergiou; Eleanna V Salgami; Dimitris G Tzamouranis; Leonidas G Roussias
Journal:  Am J Hypertens       Date:  2005-06       Impact factor: 2.689

6.  Prevalence, persistence, and clinical significance of masked hypertension in youth.

Authors:  Empar Lurbe; Isabel Torro; Vicente Alvarez; Tim Nawrot; Rafael Paya; Josep Redon; Jan A Staessen
Journal:  Hypertension       Date:  2005-03-14       Impact factor: 10.190

Review 7.  Hypertension diagnosis and prognosis in chronic kidney disease with out-of-office blood pressure monitoring.

Authors:  Rajiv Agarwal
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-05       Impact factor: 2.894

8.  Greater impact of coexistence of hypertension and diabetes on silent cerebral infarcts.

Authors:  Kazuo Eguchi; Kazuomi Kario; Kazuyuki Shimada
Journal:  Stroke       Date:  2003-09-18       Impact factor: 7.914

9.  Does masked hypertension exist in healthy volunteers and apparently well-controlled hypertensive patients?

Authors:  I Aksoy; J Deinum; J W M Lenders; Th Thien
Journal:  Neth J Med       Date:  2006-03       Impact factor: 1.422

10.  Masked hypertension in diabetes mellitus: a potential risk.

Authors:  Kazuo Eguchi; Joji Ishikawa; Satoshi Hoshide; Thomas G Pickering; Kazuyuki Shimada; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-08       Impact factor: 3.738

View more
  19 in total

1.  High-Sensitivity Cardiac Troponin T and Risk of Hypertension.

Authors:  John W McEvoy; Yuan Chen; Vijay Nambi; Christie M Ballantyne; A Richey Sharrett; Lawrence J Appel; Wendy S Post; Roger S Blumenthal; Kunihiro Matsushita; Elizabeth Selvin
Journal:  Circulation       Date:  2015-07-07       Impact factor: 29.690

Review 2.  Diagnosis and management of patients with white-coat and masked hypertension.

Authors:  Giuseppe Mancia; Michele Bombelli; Gino Seravalle; Guido Grassi
Journal:  Nat Rev Cardiol       Date:  2011-08-09       Impact factor: 32.419

Review 3.  Genetic determinants of hypertension: an update.

Authors:  Michael Harrison; Karen Maresso; Ulrich Broeckel
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

4.  Left ventricular mass and incident hypertension in individuals with initial optimal blood pressure: the Strong Heart Study.

Authors:  Giovanni de Simone; Richard B Devereux; Marcello Chinali; Mary J Roman; Thomas K Welty; Elisa T Lee; Barbara V Howard
Journal:  J Hypertens       Date:  2008-09       Impact factor: 4.844

Review 5.  The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.

Authors:  Beje Thomas; Matthew R Weir
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

6.  Masked hypertension and its associated cardiovascular risk in young individuals: the African-PREDICT study.

Authors:  Jane E S Thompson; Wayne Smith; Lisa J Ware; Carina M C Mels; Johannes M van Rooyen; Hugo W Huisman; Leone Malan; Nico T Malan; Leandi Lammertyn; Aletta E Schutte
Journal:  Hypertens Res       Date:  2015-11-26       Impact factor: 3.872

7.  Prevalence of hypertension and prehypertension in a community-based primary health care program villages at central India.

Authors:  Ramaswamy Premkumar; John Pothen; Jeeva Rima; Shobha Arole
Journal:  Indian Heart J       Date:  2016-01-13

8.  Hypertension and End-Organ Damage in Children--Is the Picture Less Fuzzy Now?

Authors:  Tibor Fülöp; Mehul P Dixit
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-14       Impact factor: 3.738

9.  Inflammatory markers should be assessed together with cardiovascular risk factors by clinicians in masked hypertension.

Authors:  Sevket Balta; Sait Demirkol; Turgay Celik; Murat Unlu; Ugur Kucuk; Zekeriya Arslan
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-29       Impact factor: 3.738

10.  Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels.

Authors:  Dimitris P Papadopoulos; Iordanis Mourouzis; Charles Faselis; Despina Perrea; Thomas Makris; Costas Tsioufis; Vasilios Papademetriou
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-02-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.